Regulation of prolactin gene expression by vasoactive intestinal peptide and dopamine in the turkey: role of Ca signalling.

Al Kahtane A, Kannan M, Kang SW, El Halawani ME

Journal of neuroendocrinology1 Oct 2005Cited by 10 (Europe PMC)

PMID16159377DOI10.1111/j.1365-2826.2005.01352.xPepBankPUB-16159377

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In cultured turkey anterior pituitary cells, VIP increased intracellular Ca2+ concentration in a concentration- and time-dependent manner.
In plain wordsIn turkey pituitary cells, VIP raised calcium levels inside the cells, and the rise grew with concentration and time.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIntracellular Ca2+ concentration
Study
turkeyn: not reported in source
Cultured turkey anterior pituitary cells
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
VIP or the L-type Ca2+ channel activator, Bay K8644 (Bay) increased [Ca2+]i in a concentration- and time-dependent fashion
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed: (i) to investigate the effect of VIP and dopamine on [Ca2+]i of cultured turkey anterior pituitary cells and (ii) to examine the role of Ca2+ signalling in mediating the regulatory effects of VIP and dopamine on prolactin mRNA levels and prolactin release.
Report a problemFND-1615937701

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In cultured turkey pituitary cells, a D2 dopamine receptor agonist or the L-type Ca2+ channel blocker verapamil abolished the rise in intracellular Ca2+ caused by VIP.
In plain wordsIn turkey pituitary cells, a dopamine receptor agonist or a calcium channel blocker stopped the calcium rise caused by VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseVIP-induced Ca2+ rise blocked by D2 agonist or verapamil
Study
turkeyn: not reported in source
Cultured turkey anterior pituitary cells
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
an effect abolished by preincubating the cells with R(-)-propylnorapomorphine HCl, a D2 dopamine receptor agonist (D2AG) or Verapamil (VR), a specific L-type Ca2+ channel blocker.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed: (i) to investigate the effect of VIP and dopamine on [Ca2+]i of cultured turkey anterior pituitary cells and (ii) to examine the role of Ca2+ signalling in mediating the regulatory effects of VIP and dopamine on prolactin mRNA levels and prolactin release.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1615937702
03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In cultured turkey pituitary cells, verapamil or a D2 dopamine agonist reduced the stimulatory effect of VIP or Bay K8644 on prolactin expression and release.
In plain wordsIn turkey pituitary cells, verapamil or a dopamine agonist reduced the boost that VIP gave to prolactin production and release.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseProlactin mRNA and release after VIP/Bay stimulation with verapamil or D2 agonist
Study
turkeyn: not reported in source
Cultured turkey anterior pituitary cells
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Similarly, either VR or D2Ag diminished the VIP/Bay stimulatory effect on prolactin expression and release.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed: (i) to investigate the effect of VIP and dopamine on [Ca2+]i of cultured turkey anterior pituitary cells and (ii) to examine the role of Ca2+ signalling in mediating the regulatory effects of VIP and dopamine on prolactin mRNA levels and prolactin release.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1615937703
04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In cultured turkey pituitary cells, depleting intracellular Ca2+ stores with thapsigargin or neomycin did not change basal or VIP-stimulated prolactin mRNA levels.
In plain wordsIn turkey pituitary cells, emptying internal calcium stores did not change prolactin mRNA, with or without VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP-stimulated prolactin mRNA after depletion of Ca2+ stores
Study
turkeyn: not reported in source
Cultured turkey anterior pituitary cells
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
On the other hand, pretreatment of pituitary cells with thapsigargin (TG) or neomycin (NEO), to deplete the intracellular Ca2+ stores, showed no effect on basal or VIP-stimulated prolactin mRNA levels
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed: (i) to investigate the effect of VIP and dopamine on [Ca2+]i of cultured turkey anterior pituitary cells and (ii) to examine the role of Ca2+ signalling in mediating the regulatory effects of VIP and dopamine on prolactin mRNA levels and prolactin release.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1615937704
05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In cultured turkey pituitary cells, neomycin partially inhibited VIP-induced prolactin release, and thapsigargin did not.
In plain wordsIn turkey pituitary cells, neomycin partly reduced the prolactin release caused by VIP. Thapsigargin did not.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseVIP-induced prolactin release after neomycin or thapsigargin
Study
turkeyn: not reported in source
Cultured turkey anterior pituitary cells
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
although VIP-induced prolactin release was partially inhibited by NEO but not TG.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed: (i) to investigate the effect of VIP and dopamine on [Ca2+]i of cultured turkey anterior pituitary cells and (ii) to examine the role of Ca2+ signalling in mediating the regulatory effects of VIP and dopamine on prolactin mRNA levels and prolactin release.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1615937705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.